ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Analyst Ratings
USA - NASDAQ:ARWR - US04280A1007 - Common Stock
39.61 USD
-2.78 (-6.56%)
39.57 USD
-0.04 (-0.1%)
ChartMill assigns a Buy % Consensus number of 79% to ARWR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 49.27. This target is 24.4% above the current price.
ARWR was analyzed by 20 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ARWR.
In the previous month the buy percentage consensus was at a similar level.
ARWR was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-14 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-29 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2024-11-27 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-27 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-09-26 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2024-07-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-17 | Chardan Capital | Maintains | Buy -> Buy |
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What is the price target for ARWR stock?
20 analysts have analysed ARWR and the average price target is 49.27 USD. This implies a price increase of 24.4% is expected in the next year compared to the current price of 39.61.
Can you provide the consensus rating for ARROWHEAD PHARMACEUTICALS IN stock?
The consensus rating for ARROWHEAD PHARMACEUTICALS IN (ARWR) is 79 / 100 . This indicates that analysts generally have a positive outlook on the stock.